Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014
-
date post
18-Oct-2014 -
Category
Health & Medicine
-
view
803 -
download
0
description
Transcript of Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014
![Page 1: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/1.jpg)
Screening in ARDRobert A Smith, PhD
American Cancer SocietyAtlanta, GA
International Conference on Monitoring and Surveillance of Asbestos-Related Diseases
2014
11-13 February 2014, Hanasaari Cultural Center, Espoo, Finland
![Page 2: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/2.jpg)
History of Guidelines for Lung Cancer Screening
• Before 1980, the American Cancer Society (ACS) recommended annual chest x-ray and sputum cytology for asymptomatic persons at high risk for lung cancer.
• In 1980, the ACS concluded “lung cancer screening….has not been demonstrated to be a benefit in reducing mortality”
![Page 3: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/3.jpg)
The Existing Evidence was Limited
• A review of early lung screening trial methodology revealed numerous shortcomings, including:– High rates of control group contamination– Low statistical power– Duration of screening and follow-up was too short– Possible ascertainment problems…underdiagnosis in
the control group – But,……there still was not compelling evidence of
reduced mortality associated with screening
![Page 4: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/4.jpg)
International Conference on the Prevention and Early Diagnosis of Lung Cancer, Varese, Italy, 1998
• An important aspect of the Conference was a review of new technology that holds the promise of substantial mortality reduction from lung cancer.
• Rigorous and rapid evaluation of these new technologies is essential in order to ensure confidence in their efficacy, and timely application of their findings.
• It is especially important that investigation of new early detection technologies receive high scientific and public health priority.
![Page 5: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/5.jpg)
Lung Cancer Screening with Low Dose Spiral CT, Lancet 1999
• In the New York ELCAP, low-dose CT was associated with a 5-fold difference compared with chest X-ray in the detection of early stage, resectable lung cancers.
Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening Lancet. 1999;354:99-105.
![Page 6: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/6.jpg)
![Page 7: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/7.jpg)
American Cancer Society Guidance on Lung Cancer Screening, 2001
• ACS does not recommend lung cancer screening
• ACS discourages testing in a setting that is not linked to multidisciplinary specialty groups for diagnosis and follow-up.
• Individuals who choose to undergo testing should have access to testing and follow-up that meet state-of-the-art standards, with informed decision-making at every step of an ongoing process.
![Page 8: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/8.jpg)
United States Preventive Services Task Force Statement on Lung Cancer Screening, 2004
• The USPSTF found fair evidence that screening with LDCT, chest radiographs, or sputum cytology can detect lung cancer at an earlier stage than lung cancer would be detected in an unscreened population; however, the USPSTF found poor evidence that any screening strategy for lung cancer decreases mortality.
• Because of the invasive nature of diagnostic testing and the possibility of a high number of false-positive tests in certain populations, there is potential for significant harms from screening.
• Therefore, the USPSTF could not determine the balance between the benefits and harms of screening for lung cancer (I Rating).
Ann Intern Med 2004;140:738-9.
![Page 9: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/9.jpg)
October 28, 2010NCI Announces Low Dose CT Screening was
Associated with Reduced Lung Cancer Deaths
![Page 10: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/10.jpg)
There were 20% fewer lung cancer deaths in the LDCT arm compared with the CXR arm. There were 6.7% fewer deaths from all causes in the LDCT arm compared with the CXR arm.
![Page 11: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/11.jpg)
Predicted cumulative lung cancer mortality per thousand randomized in hypothetical study and control groups, with relative risks, by years of follow-up
Year Cumulative mortality per 1,000 in
RR
Study group Control group1 0.8 0.8 1.002 2.5 2.6 0.953 4.4 5.2 0.854 6.6 8.3 0.795 9.1 11.7 0.776 11.9 15.3 0.787 15.1 19.1 0.798 18.5 22.9 0.819 22.1 26.8 0.8310 25.9 30.7 0.84
After year 5 the effect of screening is diluted by deaths from cases that arise after screening has stopped
![Page 12: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/12.jpg)
PLCO Trial of Lung Cancer Screening with Chest Radiograph
• Randomized controlled trial, with enrollment from 11/1993 through 7/2001
• 154,901 participants aged 55 through 74 years
• 77,445 invited to 4 rounds of annual screening
• 77,456 assigned to usual care• All diagnosed cancers, deaths,
and causes of death were ascertained through the earlier of 13 years of follow-up or until December 31, 2009.
JAMA. 2011;306(17):1865-1873
![Page 13: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/13.jpg)
Lung Cancer Mortality in the PLCO by Year
Overall, there was no benefit associated with 4 rounds of CXR in the PLCO. However, if the comparison is limited to 6 years from randomization, there were 11% fewer lung cancer deaths in the CXR arm compared with the control group.
JAMA, November 2, 2011—Vol 306, No. 17
![Page 14: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/14.jpg)
Management of Positive Findings in Lung Cancer Screening: Emerging Protocols
• Screening for lung cancer with LDCT is challenging due to the high prevalence of noncalcified pulmonary nodules detected in asymptomatic subjects who have an increased risk for lung cancer
![Page 15: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/15.jpg)
One of the most significant challenges in the implementation of lung cancer screening will be the management of positive findings
Approximately 40% of adults experienced a false positive finding during 3 rounds of LDCT screening.
![Page 16: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/16.jpg)
Nodule Size vs. Volume
• Historically, workup and surveillance has been based on nodule size and growth.– Fleishner Society – IELCAP– NLST– Nagano, Japan– Italian RCTs– Mayo– Etc
• Newer nodule management protocols are based on tumor volume and volume doubling time
![Page 17: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/17.jpg)
Management of Lung Nodules Detectedby Volume CT Scanning in the NELSON trial
• The NELSON strategy for workup entails the use of the volume and volume-doubling time of a noncalcified nodule as the main criteria for deciding on further action.
NEJM 2009:361;23
![Page 18: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/18.jpg)
NELSON Volume and Volume Doubling Time Nodule Management Protocol
NEJM 2009:361;23 Supplementary Appendix
![Page 19: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/19.jpg)
Using Lung Lesion Size Alone as the Definition of a Positive Result
• Objective: Assess alternative thresholds for the definition of a positive test.
• Measure the frequency of solid and part-solid pulmonary nodules and the rate of lung cancer diagnosis by using current (5 mm) and more restrictive (7 – 8 mm) thresholds of nodule diameter
Ann Intern Med. 2013;158:246-252.
![Page 20: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/20.jpg)
In the ELCAP Study, there were 21,136 participants, 12, 078 with a nodule ≥ 1 cm, and
3,396 with a nodule ≥ 5 cm
![Page 21: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/21.jpg)
Frequency of Positive Test Results (%) and Lung Cancer
16%
10%
7%5%
4%
![Page 22: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/22.jpg)
American Cancer Society & U.S. Preventive Services Task Force Guidelines for LDCT Lung
Cancer Screening, 2013
![Page 23: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/23.jpg)
Comparing ACS & USPSTF Lung Cancer Screening Recommendations
Recommendation ACS USPSTF
Target Population--Age 55-74 55-80
Target Population—Smoking History ≥ 30 pack years ≥ 30 pack years
Time Since Cessation ≤ 15 years ≤ 15 years
General Health Status Good
Cessation of Screening Poor health;Age > 75
Poor health; Age > 81;> 15 years since cessation
Shared Decision Making
Smoking Cessation
![Page 24: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/24.jpg)
![Page 25: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/25.jpg)
Note that the NCCN Guidelines define 2 high risk groups based on(1) smoking History, and (2) smoking history & 1 additional risk factor
![Page 26: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/26.jpg)
Agents that are identified specifically as carcinogens targeting the lungs:silica, cadmium, asbestos, arsenic, beryllium, chromium, diesel fumes, and nickel.
![Page 27: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/27.jpg)
![Page 28: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/28.jpg)
Current Lung Cancer Screening Guidelines
2013
United States Preventive Services Task Force (USPSTF
2013 Screen Ages 55-80, ≥ 30 pack years; smoking cessation within previous 15 years, stop screening when time since cessation > 15 years, make shared decision with physician
![Page 29: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/29.jpg)
Lung Cancer Risk in Former Smokers
• Smoking cessation is beneficial at any age
• Greatest benefit accrues when cessation occurs at a young age
• Age at cessation has a major impact on subsequent lung cancer risk
![Page 30: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/30.jpg)
Lung cancer deaths by age for never, former and current smokers (Halpern, et al. JNCI 1993;85(6)
Current Smokers
Never Smokers
Quit age 60-64
Quit age 55-59
Quitting after age 50 reduces the risk of lung cancer death compared with current smokers, but following a plateau after cessation, risk of lung cancer death rises significantly
![Page 31: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/31.jpg)
This slide is from an imaging center in Atlanta, using GROUPON to promote its services
Posted on May 29, 2013
![Page 32: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/32.jpg)
![Page 33: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/33.jpg)
Lung Cancer Screening Guidelines are Likely to Evolve over Time
• Other RCT publications• Demonstration projects results• Observational studies will provide data on
service screening outcomes• Applied research will identify strategies to
improve sensitivity and specificity• New technology will offer new strategies• The result…broader spectrum of tailored
protocols based on risk
![Page 34: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/34.jpg)
European Trials of Lung Cancer Screening
![Page 35: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/35.jpg)
European Randomized Controlled Trials
• 6 Ongoing trials which have enrolled 32,000 people
• ~ 150,000 person-years of FU• UKLS trial has started (4,000)• NELSON final results (mortality data) 2015
![Page 36: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/36.jpg)
Differences between NLST and European RCT’s
• NLST : Chest x-ray in control arm• EUCT: no screening in control arm
• NLST: 1-yr screen interval, 3 rounds• EUCT: different intervals and number of rounds
• NLST: 2D evaluation• EUCT: 2D and 3D evaluation
![Page 37: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/37.jpg)
• Screening of asbestos-exposed populations can be carried out for practical and scientific purposes. There are 4 goals of screening: (i) to identify high risk groups, (ii) to target preventive actions, (iii) to discover occupational diseases, and (iv) to develop improved tools for treatment, rehabilitation and prevention
![Page 38: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/38.jpg)
For many years, we have fought a losing battle in our efforts to detect lung cancer early
• Helsinki Criteria (1997)• For lung diseases,
including lung cancer, “Chest X-ray examinations can include frontal and lateral roentgenograms”
• There was no direct recommendation for lung cancer screening
• “Further studies on the effectiveness of screening programs are needed.”
![Page 39: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/39.jpg)
• Emphasized the limitations of chest x-ray surveillance for lung cancer, other than “Occasionally, a few early-stage lung cancers are also found.”
• The value of spiral CT is sufficiently compelling that clinicians and others should consider its use for case evaluation and the clinical management of those at high risk of lung cancer.
2000
![Page 40: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/40.jpg)
Why consider screening asbestos-exposed workers with LDCT?
• Screening for occupational disease is mandatory and regulated by authorities– X-ray screening for lung cancer is not effective are wastes
resources– The value of CT screening has now been established– The asbestos-exposed cohort is aging—window of
opportunity to reduce premature deaths– Asbestos-induced lung cancer shows its peak incidence
now – lung cancer screening may also detect beneficial
information regarding COPD and atherosclerosis (and probably reduce all-cause mortality)
![Page 41: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/41.jpg)
Screening for Asbestos Related Lung Cancer
•Area 1: We posed the question: “Is there sufficient
evidence from studies of former and current smokers that
lung cancer screening of asbestos exposed workers with
LDCT can be recommended?
•If so, the fundamental question relates to the risk
threshold for inclusion, caused either by asbestos
exposure alone or by the combination of asbestos
exposure and smoking.
![Page 42: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/42.jpg)
Area 1: Screening for Asbestos Related Lung Cancer--Methodology
• Three SRs of LDCT screening for lung cancer were identified
– Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT
screening for lung cancer: a systematic review. JAMA 2012;307:2418-
29
– Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ,
Campbell D. Screening for lung cancer (Review). The Cochrane
Library, Issue 6, 2013.
– Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer
with low-dose computed tomography: a systematic review to update the
US Preventive services task force recommendation. Annals of internal
medicine 2013;159:411-20.
![Page 43: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/43.jpg)
Comparison
Area 1: Systematic Reviews of Lung Cancer Screening with LDCT
ASCO, Etc. ( 2012) Cochrane (2013) USPSTF (2013)
Main Conclusions
LDCT screening may benefit individuals at an increased risk for lung cancer, but uncertainty exists about the potential harms of screening and the generalizability of results.
Annual LDCT is associated with a reduction in lung cancer death in high risk smokers and former smokers. Further data are required on the cost effectiveness of screening, and the relative harms and benefits of screening across a range of different risk groups and settings. Evidence does not support lung cancer screening with CXR or sputum cytology.
Good evidence shows LDCT can significantly reduce mortality from lung cancer. However, there are significant harms associated with screening that must be balanced with the benefits.
AREA 1: Review of Recent Systematic Reviews of LungCancer Screening
![Page 44: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/44.jpg)
Area 1: Screening for Asbestos Related Lung Cancer--Methodology
•Second systematic review: Identify
literature on CT screening for lung
cancer among asbestos-exposed
workers. 158 papers were identified,
and 12 met inclusion criteria (non-
review, non cases series).
![Page 45: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/45.jpg)
Studies of Lung Cancer Screening in Asbestos Exposed Workers
• The published articles of asbestos-exposed persons typically:– Are case series– Have limited number of subjects– Have no control groups– Have little follow-up data on mortality
• They provide only inferential evidence about the efficacy of lung cancer screening in adults with a history of asbestos exposure.
• Therefore, the assessment of how asbestos exposed workers should be followed up must mainly be based on risk assessment and the outcome of the RCTs of LDCT screening for lung cancer.
![Page 46: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/46.jpg)
Characteristics of Studies of Lung Cancer Screening in Asbestos Exposed Workers
Characteristic Findings
Year of Publication 1998 - 2012
Age Range/Median 32 – 86, Mean 57 -66
Asbestos Exposure Highly variable indicators, e.g. “in contact at work”High (current) > 1 yr. vs. High (not current) ≥ 10 yrsSingle occupation group, exposure by years at work“Definite”10 years / > 20 yrs> 20 yrs, or pleural plaquesAsbestosis, or pleural plaques and > 10 pack years
Smoking Highly variable indicators, ie, pack years, years smoking, median years smoking, etc.Highly variable smoking exposure (including no smoking)—years smoked, median years smoked, mean/median pack yearsVariable proportions of current and former smokers, and total exposures Combinations: > 10 + asbestos, > 10 if no asbestos, etc.
![Page 47: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/47.jpg)
Characteristics of Studies of Lung Cancer Screening in Asbestos Exposed Workers (continued)
Characteristic Findings
CT Methodology Variable slice thickness (5mm, 10 mm); mA (10 – 125); or no discussion
Criteria for Positive Finding
Variable: Any suspicious lesion; ELCAP protocol;1-6 > 2mm; lesion ≥ 2mm, 5mm, 6mm, 20 mm; variable size if solid vs. non-solid
Screening Protocol Highly variable: Baseline only (9 studies); 2 rounds/biennial (1 study); baseline—annual repeat screening (1 study); 1-3 rounds/annual (1 study)
Control group No (10 studies); Patient are their own controls CT vs. Chest (2 studies)
![Page 48: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/48.jpg)
Select Findings from the Systematic Review of LDCT Screening for ARD
Study # Screened 1st Screen Suspicious Finding
Number of Lung Cancers (%)
Callol, 2007 466 21% 1 (0.2%) 1st Rnd5 (1%) 2nd Rnd
Clin, 2009 719 23% 18 (2.2%)
Clin, 2011 5,662 17% 50 (0.9%)
Das, 2007 187 87% 9 (4.8%)
Fasola, 2007 1,045 44% 9 (0.9%)
Greenberg, 2012 1,182 52% 30 (2.5%)
Loewen,2007 169 57% 13 (7%)
Lynch, 1988 260 6% 2 (0.8%)
Mastrangalo, 2008 1,119 21% 5 (0.4%)
Roberts, 2009 516 17.6% 4 (0.8%)
Tiitola, 2002 602 18.5% 5 (0.8%)
Vierikko, 2007 633 13.6% 5 (0.8%)
![Page 49: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/49.jpg)
• Cohort studies involving chest CT screening for lung cancer in former asbestos exposed workers.
• Inclusion criteria: asbestos exposure, cohort studies (minimal number of 10 individuals), non case-study design
• Primary outcome: Number of lung cancer cases at prevalent screening• 7 studies met inclusion criteria
![Page 50: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/50.jpg)
Select Findings from the Systematic Review of LDCT Screening for ARD—Common studies identified by Area 1 workgroup and Olliel,
et al. (2014)
Study # Screened
1st Screen Suspicious
Finding
Number of Lung Cancers
(%)Clin, 2009 719 23% 18 (2.2%)Das, 2007 187 87% 9 (4.8%)Fasola, 2007 1,045 44% 9 (0.9%)Mastrangalo, 2008
1,119 21% 5 (0.4%)
Roberts, 2009 516 17.6% 4 (0.8%)Tiitola, 2002 602 18.5% 5 (0.8%)Vierikko, 2007 633 13.6% 5 (0.8%)
![Page 51: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/51.jpg)
Lung cancer prevalence and confidence intervals of seven studies.
--Baseline screening detected 49 asymptomatic lung cancers among 5074asbestos-exposed workers.--The prevalence of all lung cancers detected by CT screening in asbestos-exposed workers was 1.1% (CI 95%: 0.6%-1.8%).--18 were stage 1, accessible to complete removal surgery.
![Page 52: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/52.jpg)
Conclusion
• There already is considerable, and growing evidence supporting the benefits of LDCT in detection early lung cancer in high risk (current and former smokers
• There is considerably less information about the benefits of LDCT screening in select groups at equivalent risk
• The challenge--Identification of high risk asbestos exposed workers who do not meet the minimum absolute risk for the NLST based on smoking history alone (1.34% over 6 years)
![Page 53: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/53.jpg)
International Conference on Monitoring and Surveillance of Asbestos-Related Diseases 2014
11-13 February 2014, Hanasaari Cultural Center, Espoo, Finland
Recommendation from Workgroup 1
Based on the lung cancer LDCT screening studies, the dose-
response risk of lung cancer in asbestos-exposed workers,
and the established relationship on interaction of asbestos
exposure and smoking, we recommend the following groups
for LDCT screening
1) Workers with any asbestos exposure and a smoking history equal to
the entry criteria of the NLST study
2) Workers with asbestos exposure with or without a smoking history
which alone or together would yield an estimated lung cancer risk level
equal to the entry criteria of the NLST study
![Page 54: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/54.jpg)
Area 1: Recommendation (continued)•First, existing databases should be assessed for the potential to verify the
generalizability of the Lung Cancer Screening RCT results to asbestos exposed
adults.
•Second, since our recommendations are based on inferential evidence and
modeling, the introduction of lung screening in asbestos exposed workers
must be viewed as a research program in order to verify these assumptions.
We strongly recommend an international multicenter research project on
the effect of LDCT screening among asbestos exposed workers to acquire the
necessary evidence.
![Page 55: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/55.jpg)
Conclusion• It is important to heed the lessons learned from
the implementation of screening for breast, cervix, colorectal and prostate cancers.
• The combination of insistence on best practices, on-going program evaluation, and attempts to maximize benefits and minimize harms is critical to success.
• There can be no shortcuts.
![Page 56: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/56.jpg)
Acknowledgements
Tapio Vehmas
Anthony B Miller
Kurt Straif
Nea Malila
Riitta Sauni
Chris Berg (NLST)
![Page 57: Screening in Asbestos-related diseases (lung cancer) at Helsinki Asbestos 2014](https://reader033.fdocuments.in/reader033/viewer/2022061105/544351ecb1af9f310a8b497a/html5/thumbnails/57.jpg)
Thank you